Fund Details
HG
Hengdian Group Capital
Overview
Investment portfolio
3rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Tianbing Technology | Jul 2026Led | $29 MOther Equity | |
Jixing Pharmaceuticals | Jan 2026Participated | $287 MSeries D | |
Solu Therapeutics | Apr 2025Participated | $41 MSeries A | |
Tianbing Technology | Jul 2026Led | $29 MOther Equity | |
Jixing Pharmaceuticals | Jan 2026Participated | $287 MSeries D | |
Solu Therapeutics | Apr 2025Participated | $41 MSeries A |
3 Items
3
Items
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 1 |
| Series C+ | 0 | 1 |
| Other Equity | 1 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Apr '25 | 1 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 1 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 2 |
| Travel & Hospitality | 1 |
| Manufacturing | 1 |
| Space & Frontier Tech | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 0 |
| $25M-$50M | 2 |
| $50M-$100M | 0 |
| $100M-$250M | 0 |
| $250M-$500M | 1 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| China | 2 |
| United States | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Adage Capital Management | 1 |
| Alexandria Venture Investments | 1 |
| Astellas Venture Management | 1 |
| Biovision Ventures | 1 |
| DCVC Bio | 1 |
| Eli Lilly and Company | 1 |
| HBM Healthcare Investments | 1 |
| Invus | 1 |
| Longwood Fund | 1 |
| Pappas Capital | 1 |
| RA Capital Management | 1 |
| RTW Investments | 1 |
| Sante Ventures | 1 |
| Silver Arc Private Capital | 1 |
| SR One | 1 |
| SymBiosis | 1 |
| TCGX | 1 |
| The Leukemia & Lymphoma Society | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 1 | 33% |
| Participating | 2 | 67% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 100% |
| Co-led | 0 | 0% |
Team
No team members found for this fund.